Immuron Limited (AU:IMC) has released an update.
Immuron Limited invites shareholders to a webinar hosted by CEO Steven Lydeamore on August 8, 2024, to discuss the Phase 2 trial of IMM-124E (Travelan®) and future company plans. The event will include a presentation and a live Q&A session, with a recorded copy available post-event. Immuron specializes in developing oral antibody-based therapies for infectious diseases, including travelers’ diarrhea and C. difficile infections.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
